Maja J. De Jonge

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Jordi Rodón, Irene Braña, Lillian L. Siu et al. · Investigational New Drugs · 2014 · 188 citations

Medicine, Pharmacology, Advanced Solid Tumors +7

Capmatinib (INC280) in <i>METΔex14</i>-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

Juergen Wolf, Takashi Seto, Ji‐Youn Han et al. · Journal of Clinical Oncology · 2019 · 111 citations

Geometry Mono-1, Met-amplified Advanced Nsclc, Pathology +17

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Joonil Jung, Joon Sang Lee, Mark A. Dickson et al. · Nature Communications · 2016 · 92 citations · Full text

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García et al. · Clinical Cancer Research · 2015 · 68 citations · Full text

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

José Baselga, Maja J. De Jonge, Jordi Rodón et al. · Journal of Clinical Oncology · 2010 · 53 citations

Pathology, Pi3k Inhibitor, Pharmacotherapy +16